Company news
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news
Every Neurocrine Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 5
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
July 14, 2022
Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
June 13, 2022
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 8, 2022
Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022
June 6, 2022
Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
June 6, 2022
Neurocrine Biosciences Announces Repurchase of Convertible Notes
May 24, 2022
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
May 23, 2022
Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
May 12, 2022
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
May 4, 2022
Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
May 3, 2022
Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
May 2, 2022
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
April 13, 2022
Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
April 1, 2022
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
March 28, 2022
Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
March 28, 2022
Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
March 24, 2022
Neurocrine Biosciences to Present at Stifel 2022 CNS Days
March 21, 2022
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
February 11, 2022
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results
January 25, 2022
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
January 6, 2022
Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease
December 7, 2021
Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
November 30, 2021
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
November 22, 2021
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results
November 1, 2021
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021
November 1, 2021
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
October 16, 2021
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
October 11, 2021
Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic
October 8, 2021
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease
August 5, 2021
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
August 3, 2021
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
July 19, 2021
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
May 5, 2021
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
April 16, 2021
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
April 14, 2021
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
March 2, 2021
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
February 4, 2021
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results
January 20, 2021
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
January 8, 2021
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results
November 9, 2020
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
October 6, 2020
Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
September 14, 2020
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
August 3, 2020
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
July 13, 2020
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
June 16, 2020
Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy
May 11, 2020
Neurocrine Biosciences Reports First Quarter 2020 Financial Results
May 6, 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
April 27, 2020
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results
April 15, 2020
Neurocrine Biosciences Provides COVID-19 Business Update
April 3, 2020